Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a

Vaccine

Volumn 25, Issue 25, 2007, Pages 4828-4836

  Shim, Doo Hee ^a   Chang, Sun Young ^a   Park, Sung Moo ^a   Jang, Hyun ^b   Carbis, Rodney ^b   Czerkinsky, Cecil ^b   Uematsu, Satoshi ^c   Akira, Shizuo ^c   Kweon, Mi Na ^a  

^a Seoul National University   (South Korea)

^b International Vaccine Institute   (South Korea)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Mucosal immunity; Ribosomal vaccine; S. flexneri 2a; Secretory IgA

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; SHIGELLA RIBOSOME BASED VACCINE; SHIGELLA VACCINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; COLITIS; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOGENICITY; INFECTION PREVENTION; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHIGELLA FLEXNERI; SHIGELLA FLEXNERI 2A; SHIGELLOSIS; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; DYSENTERY, BACILLARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; LIPOPOLYSACCHARIDES; LUNG; MICE; MICE, INBRED BALB C; O ANTIGENS; PNEUMONIA; RIBOSOMES; SHIGELLA FLEXNERI; SHIGELLA VACCINES; VACCINATION;

EID: 34249295519     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.03.050     Document Type: Article

References (36)

1. Niyogi S.K. Shigellosis. J Microbiol 43 2 (2005) 133-143
2. Sansonetti P.J. War and peace at mucosal surface. Nat Rev Immunol 4 12 (2004) 953-964
3. McGhee J.R., and Kiyono H. The mucosal immune system. In: Paul W.E. (Ed). Fundamental Immunology. 4th ed. (1999), Lippincott-Raven Publishers 909
4. Czerkinsky C., and Holmgren J. Mucosal immunity and vaccines. Nature Med 11 4 (2005) S45-S53
5. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 77 8 (1999) 651-666
6. Passwell J.H., Harlev E., Ashkenazi S., Chu C., Miron D., Ramon R., et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 69 3 (2001) 1351-1357
7. Coster T.S., Hoge C.W., VanDeVerg L.L., Hartman A.B., Oaks E.V., Vankatesan M.M., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67 7 (1999) 3437-3443
8. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 72 2 (2004) 923-930
9. Berry E.M., Wang J., Wu T., Davis T., and Levine M.M. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 24 18 (2006) 3728-3734
10. Gregory R.L. Microbial ribosomal vaccines. Rev Infect Dis 8 2 (1986) 208-217
11. Levenson V.I., Chernokhvostova E.V., Lyubinskaya M.M., Salamatova S.A., Dzhikidze E.K., and Stasilevitch Z.K. Parenteral immunization with Shigella ribosomal vaccine elicits local IgA response and primes for mucosal memory. Int Arch Aller Appl Immun 87 1 (1988) 25-31
12. Levenson V.I., Subbotina I., Gofman I.L., and Iarovaia L.M. Ribosomal dysentery vaccine. I. Method of production, physical and chemical properties. Zh Mikrobiol Epidemiol Immunobiol 3 (1978) 60-65
13. Kweon M.N., Yamamoto M., Watanabe F., Tamura S., Van Ginkel F.W., and Kiyono H. A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J Infect Dis 186 9 (2002) 1261-1269
14. Yamamoto S., Kiyono H., Yamamoto M., Imaoka K., Fujihashi K., Van Ginkel F.W., et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 94 10 (1997) 5267-5272
15. + T cells in nasopharyngeal-associated lymphoreticular tissue. J Immunol 170 4 (2003) 1754-1762
16. Yamamoto M., Kweon M.N., Rennert P.D., Hiroi T., Fujihashi K., McGhee J.R., et al. Role of gut-associated lymphoreticular tissues in antigen-specific intestinal IgA immunity. J Immunol 173 2 (2004) 762-769
17. Kweon M.N., Yamamoto M., Rennert P.D., Park E.J., Lee A.Y., Chang S.Y., et al. Prenatal blockage of lymphotoxin β receptor and TNF receptor p55 signaling cascade resulted in the acceleration of tissue genesis for isolated lymphoid follicles in the large intestine. J Immunol 174 7 (2005) 4365-4372
18. Mallett C.P., Hale T.L., Kaminski R.W., Larsen T., Orr N., Cohen D., et al. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect Immun 63 6 (1995) 2382-2386
19. Akira S., and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4 7 (2004) 499-511
20. Wijburg O.L., Uren T.K., Simpfendorfer K., Johansen F.E., Brandtzaeg P., and Strugnell R.A. Innate secretory antibodies protect against natural Salmonella typhimurium infection. J Exp Med 203 1 (2006) 21-26
21. Lieberman M.M., Wright G.L., Wolcott K.M., and McKissock-Desoto D.C. Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains. Infect Immun 29 2 (1980) 489-493
22. Serrano E., Demanez Z.P., Morqon A., Chastang C., and Van Cauwenberge P. Effectiveness of ribosomal fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction of Kp (Ribomunyl) in the prevention of clinical recurrences of infectious rhinitis. Results of a multicenter double-blind placebo-controlled study. Eur Arch Otorhinolaryngol 254 8 (1997) 372-375
23. Levenson V.I., and Egorova T.P. Polysaccharide nature of O antigen in protective ribosomal preparations from Shigella: experimental evidence and implications for the ribosomal vaccine concept. Res Microbiol 141 6 (1990) 707-720
24. Brandtzaeg P., and Pabst R. Let's go mucosal: communication on slippery ground. Trends Immunol 25 11 (2004) 570-577
25. Kurohane K., Kobayashi C., and Imai Y. Facilitated production of secretory IgA against Shiga toxin B subunits by intranasal application of antigen-coated polystyrene microspheres. Microbiol Immunol 49 2 (2005) 149-154
26. Shim D.H., Suzuki T., Chang S.Y., Park S.M., Sansonetti P.J., Sasakawa C., et al. New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies. J Immunol 178 4 (2007) 2476-2482
27. Singer M., and Sansonetti P.J. IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of Shigella-induced colitis. J Immunol 173 6 (2004) 4197-4206
28. Zhang Z., Jin L., Champion G., Seydel K.B., and Stanley Jr. S.L. Shigella infection in a SCID mouse-human intestinal xenograft model: role for neutrophils in containing bacterial dissemination in human intestine. Infect Immun 69 5 (2001) 3240-3247
29. Hertz C.J., Kiertscher S.M., Godowski P.J., Bouis D.A., Norquard M., Roth M.D., et al. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 166 4 (2001) 2444-2450
30. Lee S.E., Kim S.Y., Jeong B.C., Kim Y.R., Bae S.J., Ahn O.S., et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 74 1 (2006) 694-702
31. Pasare C., and Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 438 7066 (2005) 364-368
32. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314 5807 (2006) 1936-1938
33. Normier G., Pinel A.M., Dussourd d'Hinterland L., Wiqzell H., and Binz H. Ribosomes as carriers for antigenic determinants of the surface of micro-orgamisms. Dev Biol Stand 77 (1992) 79-85
34. Venneman M.R., and Bigley N.J. Isolation and partial characterization of an immunogenic moiety obtained from Salmonella typhimurium. J Bacteriol 100 1 (1969) 140-148
35. Kita E., Oku D., Nishikawa F., Emoto M., Yasui K., and Kashiba S. Requirement of the conformational stability of a Salmonella ribosomal vaccine for its mouse protection. FEMS Microbiol Immunol 3 4 (1991) 229-239
36. Youmans A.S., and Youmans G.P. Factors affecting immunogenic activity of mycobacterial ribosomal and ribonucleic acid preparations. J Bacteriol 99 1 (1969) 42-50